Key result
Oral anticoagulant therapy in patients with non-valvular atrial fibrillation and a single additional stroke risk factor reduces the risk of stroke, systemic embolism, or death compared to no therapy or aspirin.
Why the study?
Does oral anticoagulant therapy reduce stroke, systemic embolism, or death in patients with non-valvular atrial fibrillation and a single additional stroke risk factor?
Population
Patients with non-valvular atrial fibrillation and a single additional stroke risk factor.
Comparison
Oral anticoagulant therapy vs No therapy or aspirin
Design
Review
Authors
Loading...
Supports net clinical benefit of OAC in NVAF with one risk factor; leaves open practice change pending randomized confirmation.
Does oral anticoagulant therapy reduce stroke, systemic embolism, or death in patients with non-valvular atrial fibrillation and a single additional stroke risk factor?
Oral anticoagulant therapy provides a positive net clinical benefit in atrial fibrillation patients with a single additional stroke risk factor, supporting its use over aspirin or no therapy.
Potpara et al. (2016) conducted a review in Non-valvular Atrial Fibrillation. Oral Anticoagulant Therapy (OAC) vs. No therapy or aspirin was evaluated. Oral anticoagulant therapy in patients with non-valvular atrial fibrillation and a single additional stroke risk factor reduces the risk of stroke, systemic embolism, or death compared to no therapy or aspirin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: